You just read:

Mirati Therapeutics Presents First Clinical Data Of Phase 1/2 Trial Of MRTX849 At The 2019 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics

News provided by

Mirati Therapeutics, Inc.

Oct 28, 2019, 16:15 ET